Aptorum Group
Manufacturing · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
17 Hanover Sq, London, Greater London, W...Phone Number
+44 2080929299Website
www.aptorumgroup.comRevenue
-Stock Symbol
APMIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Aptorum Group
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases; and (ii) the co-development of a novel molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore's Agency for Science, Technology and Research.Explore more
Aptorum Group Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aptorum Group your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Aptorum Group has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Aptorum Group
Aptorum Group, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Aptorum Group launches new products
Earning: See what the market has to say on Aptorum Group recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Aptorum Group has new funding data
Check out if Aptorum Group is spiking on competitors!
Click to see if Aptorum Group had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Aptorum Group
Find more new buyers
Compare Similar Companies to Aptorum Group
Compare insights from companies similar to Aptorum Group, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Aptorum Group is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Aptorum Group is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Aptorum Group.
Aptorum Group Tech Stack
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Earnings
Earnings, Finance
Mergers & Acquisitions (M&A)
Mergers & Acquisitions
Earnings
Earnings, Sales
Earnings
Earnings
Aptorum Group News & Media
Aptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR Biosciences
NEW YORK, NY, June 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company dedicated to addressing unmet medical needs, today announced that at its shareholder meeting held on June 9, 2026, its shareholders voted to approve the proposed merger transaction with DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases.Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania
NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the publication of a paper by Giliberto, et. al. titled "Development of microRNA-Based Glioblastoma Biomarkers UAptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Hong Kong, March 06, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated March 5, 2026 regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550(a)(2).Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB’s Automated APOE Testing Platform for Alzheimer’s Disease
NEW YORK, NY; NEW HAVEN, CT; PRINCETON, NJ, and TAIPEI, TAIWAN, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Instant NanoBiosensors Co., Ltd. (“INB”), a developer of cutting-edge biosensor platforms designed to improve bio
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Aptorum Group
Sign Up For FreeTo access detailed company insights
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is al... Read More
